Serum Monitoring and Phenotype Identification of Stage I Non-Small Cell Lung Cancer Patients

James R. Hocker, Subrato J. Deb, Min Li, Megan R. Lerner, Stan A. Lightfoot, Aurelien A. Quillet, R. Jane Hanas, Matthew Reinersman, Jess L Thompson, Nicole T. Vu, Thomas C. Kupiec, Daniel J. Brackett, Marvin D. Peyton, Stephen M. Dubinett, Harold M. Burkhart, Russell G. Postier, Jay S. Hanas

Research output: Contribution to journalArticle

7 Scopus citations

Abstract

A stage I non-small cell lung cancer (NSCLC) serum profiling platform is presented which is highly efficient and accurate. Test sensitivity (0.95) for stage I NSCLC is the highest reported so far. Test metrics are reported for discriminating stage I adenocarcinoma vs squamous cell carcinoma subtypes. Blinded analysis identified 23 out of 24 stage I NSCLC and control serum samples. Group-discriminating mass peaks were targeted for tandem mass spectrometry peptide/protein identification, and yielded a lung cancer phenotype. Bioinformatic analysis revealed a novel lymphocyte adhesion pathway involved with early-stage lung cancer.

Original languageEnglish (US)
Pages (from-to)1-13
Number of pages13
JournalCancer Investigation
DOIs
StateAccepted/In press - Sep 22 2017
Externally publishedYes

Keywords

  •  

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Serum Monitoring and Phenotype Identification of Stage I Non-Small Cell Lung Cancer Patients'. Together they form a unique fingerprint.

  • Cite this

    Hocker, J. R., Deb, S. J., Li, M., Lerner, M. R., Lightfoot, S. A., Quillet, A. A., Hanas, R. J., Reinersman, M., Thompson, J. L., Vu, N. T., Kupiec, T. C., Brackett, D. J., Peyton, M. D., Dubinett, S. M., Burkhart, H. M., Postier, R. G., & Hanas, J. S. (Accepted/In press). Serum Monitoring and Phenotype Identification of Stage I Non-Small Cell Lung Cancer Patients. Cancer Investigation, 1-13. https://doi.org/10.1080/07357907.2017.1373120